Open AccessAssociation of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non–Small Cell Lung Cancer
Author(s) -
Michael Leapman,
Carolyn J. Presley,
Weiwei Zhu,
Pamela R. Soulos,
Kerin B. Adelson,
Rebecca A. Miksad,
Daniel J. Boffa,
Cary P. Gross
Publication year - 2020
Publication title -
jama network open
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.278
H-Index - 39
ISSN - 2574-3805
DOI - 10.1001/jamanetworkopen.2020.7205
Subject(s) - medicine , pembrolizumab , lung cancer , retrospective cohort study , oncology , cancer , cohort , pd l1 , immunotherapy
This cohort study evaluates the association between programmed cell death ligand 1 testing and first-line immune checkpoint inhibitor use in patients with advanced non–small cell lung cancer.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom